Kenneth J. Kopecky

Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study

Marilyn L. Slovak, Kenneth J. Kopecky, Peter A. Cassileth et al. · Blood · 2000 · 1.6K citations

Medicine, Hematology, Oncology +10

Acute Myeloid Leukemia in the Elderly: Assessment of Multidrug Resistance (MDR1) and Cytogenetics Distinguishes Biologic Subgroups With Remarkably Distinct Responses to Standard Chemotherapy. A Southwest Oncology Group Study

Catherine P. Leith, Kenneth J. Kopecky, John E. Godwin et al. · Blood · 1997 · 868 citations

Medicine, Geriatric Medicine, Oncology +8

A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia

Stephen H. Petersdorf, Kenneth J. Kopecky, Marilyn L. Slovak et al. · Blood · 2013 · 633 citations

Medicine, Hematology, Pharmacology +10

Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study.

Catherine P. Leith, Kenneth J. Kopecky, I‐Ming Chen et al. · PubMed · 1999 · 579 citations · Full text

Medicine, Oncology, Pharmacology +13

FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia

Derek L. Stirewalt, Kenneth J. Kopecky, Soheil Meshinchi et al. · Blood · 2001 · 440 citations

Medicine, Molecular Genetics, Oncology +15